On May 5, 2026, the US Food and Drug Administration commissioner publicly defended the agency’s drug approval decisions, responding to criticism from the pharmaceutical industry and some members of Congress.

The Controversy

Several pharmaceutical companies have expressed dissatisfaction with the FDA’s approval pace and standards, arguing the agency has been overly cautious on certain medications. Some lawmakers have also raised concerns.

Commissioner Response

The FDA commissioner emphasized that approval standards will not be lowered under political or commercial pressure, and that protecting public health remains the agency’s top priority. The agency will continue to base approval decisions on scientific evidence.

The U.S. Food and Drug Administration has approved expanded access to daraxonrasib, a targeted pancreatic cancer drug developed by Revolution Medicines, according to The New York Times and Reuters. The decision opens the door for more patients awaiting treatment to receive a therapy that has demonstrated significant efficacy in clinical trials.

A Breakthrough Therapy

Daraxonrasib is a targeted inhibitor directed at the KRAS G12D mutation. KRAS mutations are among the most common driver alterations in pancreatic cancer, found in approximately 35% to 40% of pancreatic ductal adenocarcinoma cases. For decades, the KRAS protein was considered “undruggable” due to its structural characteristics, but a new generation of covalent inhibitors has changed that landscape.

Reuters reports that in early-stage clinical trials, daraxonrasib caused significant tumor shrinkage in some patients with advanced pancreatic cancer. Notably, the spouse of former Senator Ben Sasse has shown encouraging results on the drug, drawing widespread public attention.

What Expanded Access Means

The FDA’s expanded access program — also known as “compassionate use” — allows unapproved drugs to be used by patients with serious or life-threatening conditions who cannot enroll in clinical trials. The approval of this pathway means more patients who are ineligible for trial participation can gain early access to treatment.

The Washington Post notes that the speed of the expanded access approval reflects the FDA’s strong confidence in the drug’s efficacy data. While such approvals typically take several weeks, this one was processed in under two weeks.

The Challenge of Pancreatic Cancer

Pancreatic cancer is often called the “king of cancers” and ranks as the fourth leading cause of cancer-related death in the United States. Due to its subtle early symptoms, difficulty in detection, and limited treatment options, the five-year survival rate has long hovered around just 12%.

Revolution Medicines’ Chief Medical Officer stated: “We are pleased to work with the FDA to give more patients in desperate need the opportunity to receive daraxonrasib. This is an important step toward transforming the pancreatic cancer treatment landscape.”

Market Outlook

Industry analysts project that if daraxonrasib continues to demonstrate positive data in later-stage trials, it could receive full FDA approval by 2027. At that point, the KRAS-targeted therapy market is expected to reach tens of billions of dollars, covering indications in pancreatic cancer, colorectal cancer, and non-small cell lung cancer.

Source: The New York Times · Reuters · USA Today

Drug Background

Daraxonrasib is a selective inhibitor targeting the KRAS G12D mutation, developed by Revolution Medicines. KRAS gene mutations are one of the most common drivers of pancreatic cancer, accounting for approximately 35% to 40% of cases. For decades, KRAS mutations were considered “undruggable,” but recent technological advances have made it possible to selectively target specific KRAS mutations.

Clinical Trial Data

In early-stage clinical trials, daraxonrasib has demonstrated encouraging efficacy data. Some patients experienced significant tumor shrinkage, with disease control rates surpassing existing standard-of-care treatments. Perhaps most importantly, the drug has shown a favorable tolerability profile, with manageable side effects.

According to The New York Times, former U.S. Senator Ben Sasse is among the beneficiaries of the drug. After being diagnosed with pancreatic cancer, Sasse participated in the clinical trial and has seen his condition effectively controlled.

Expanded Access Program

The FDA’s approval of the Expanded Access Program, also known as “compassionate use,” allows patients with serious or life-threatening conditions to access investigational drugs before they receive formal approval.

This mechanism is particularly important for patients who are ineligible for ongoing clinical trials and have no other effective treatment options. Pancreatic cancer, often called the “king of cancers,” has a five-year survival rate of only about 12%, making it one of the cancer types with the most urgent need for new therapies.

Industry Significance

Analysts note that daraxonrasib’s progress is significant not only for pancreatic cancer patients but also opens new possibilities for treating other KRAS-mutated solid tumors, including colorectal cancer and non-small cell lung cancer.

Revolution Medicines’ shares rose following the announcement, reflecting market optimism about the drug’s commercial prospects. If daraxonrasib ultimately receives full FDA approval, it would represent a major milestone in pancreatic cancer treatment.

Next Steps

Revolution Medicines plans to continue advancing daraxonrasib through Phase III clinical trials to gather more comprehensive efficacy and safety data in support of full marketing approval. The company expects to report interim results from the pivotal trial within the next year.

Source: The New York Times, Reuters

The US Food and Drug Administration (FDA) announced a major initiative in late April 2026 to introduce artificial intelligence and real-time data collection systems to accelerate the drug clinical trial approval process, according to the Wall Street Journal and STAT News. This move is seen as a fundamental transformation of the drug development regulatory model.

Core Elements of the Plan

The FDA’s initiative aims to leverage AI technology for real-time analysis and evaluation of clinical trial data, rather than the traditional post-hoc review model. By deploying advanced AI algorithms, the FDA will be able to continuously monitor trial progress, identify potential safety signals and efficacy trends earlier, and thereby shorten the cycle from clinical trials to drug approval.

According to the WSJ, the plan includes the following key components:

1. Real-Time Data Pipeline: Establishing direct data transmission channels from clinical trial sites to the FDA, enabling real-time data collection and analysis.
2. AI-Assisted Review: Using machine learning models to automatically identify patterns and anomalies in trial data, assisting reviewers in making more efficient decisions.
3. Adaptive Trial Design: Encouraging pharmaceutical companies to adopt more flexible trial designs that allow protocol adjustments based on interim data during the trial.

Industry Impact

This initiative has profound implications for the pharmaceutical industry. Traditional drug development cycles typically take over 10 years and cost billions of dollars. By introducing AI and real-time data technology, the FDA could shorten the approval cycle by months or even years, significantly reducing R&D costs.

According to TipRanks analysis, this policy change is particularly beneficial for small and mid-sized biotech companies, which typically have limited resources and rely more heavily on fast and efficient approval processes.

Historical Context and Challenges

The FDA is not new to AI applications. Previously, the FDA had deployed an AI tool called “Elsa” for routine regulatory operations. However, deeply integrating AI into the clinical trial approval process still faces numerous challenges, including data privacy protection, algorithm transparency, and the need for explainability of AI-driven decisions.

Previous reports noted that the FDA experienced some errors when using AI tools internally, raising questions about the reliability of AI-assisted regulatory decisions. The FDA needs to find the right balance between innovation and prudence.

Future Outlook

The FDA’s initiative aligns with the broader trend of accelerating AI applications in healthcare globally. If successfully implemented, it could not only transform the US drug approval process but also serve as a reference model for regulatory agencies in other countries.

Source: STAT News, Wall Street Journal, TipRanks